Side-by-side · Research reference
PT-141vsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED13/41 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
PT-141
Testagen
Primary target
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Testicular tissue; proposed nuclear DNA interaction
Pathway
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
—
Unknown — no HPG axis data
Origin
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
PT-141
Testagen
Standard dose
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
—
Frequency
PRN, max 8 doses / month
Once daily or alternate days
Lower / starter dose
1 mg (off-label)
—
Evidence basis
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Animal mechanistic / in vitro onlyFedoreyeva 2011
Duration
PRN; reassess if no benefit after 8 doses
—
Reconstitution
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Sterile water or bacteriostatic saline
Timing
≥45 min before sexual activity
—
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
—
Subcutaneous
04Side Effects & Safety
Parameter
PT-141
Testagen
Flushing
Common, transient
—
Injection site reaction
Erythema, mild pain
—
Headache
Common
—
Hyperpigmentation (focal)
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
—
Hypertension (transient)
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
—
Pregnancy / OB
Contraindicated
—
Cardiovascular disease
Use caution; transient BP rise
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Testagen
- ·Active testicular malignancy
Relative Contraindications
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
PT-141
Testagen
1. Reconstitution
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Injection site
SQ — abdomen or thigh.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Needle
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.